Apremilast is an oral PDE4 approved in the United States for the treatment of active psoriatic arthritis in adults and of moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy. This evidence concerns the gene PDE4A and psoriasis vulgaris.